Table 5 Ovary and uterus related adverse events with positive signals for rosuvastatin.
Classification | PTs | Proportional rate ratio (PRR) by age groups (years) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall | 0–18 | 19–39 | 40–59 | ≥ 60 | ||||||||||||
N | PRR | χ2 | N | PRR | χ2 | N | PRR | χ2 | N | PRR | χ2 | N | PRR | χ2 | ||
Uterine neoplasms | Uterine leiomyoma | – | – | – | – | – | – | 3 | 5.01 | 6.00 | – | – | – | – | – | – |
Cervix neoplasms | Cervix carcinoma stage III | 3 | 10.86 | 16.54 | – | – | – | – | – | – | 3 | 27.88 | 43.66 | – | – | – |
Uterine disorders (excl neoplasms) | Endometrial hypertrophy | 6 | 3.06 | 6.23 | – | – | – | – | – | – | 4 | 4.77 | 8.14 | – | – | – |
